SJS Investment Consulting’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$132K Buy
5,482
+420
+8% +$11K 0.01% 200
2026
Q1
$142K Buy
5,062
+147
+3% +$3.91K 0.02% 177
2025
Q4
$122K Buy
4,915
+61
+1% +$1.54K 0.02% 179
2025
Q3
$124K Sell
4,854
-653
-12% -$16.1K 0.02% 168
2025
Q2
$133K Sell
5,507
-438
-7% -$10.2K 0.02% 119
2025
Q1
$151K Buy
5,945
+503
+9% +$13.2K 0.03% 107
2024
Q4
$144K Sell
5,442
-595
-10% -$16.1K 0.02% 109
2024
Q3
$175K Buy
6,037
+2
+0% +$58 0.03% 105
2024
Q2
$169K Sell
6,035
-248
-4% -$6.83K 0.03% 98
2024
Q1
$174K Buy
6,283
+23
+0.4% +$638 0.03% 94
2023
Q4
$180K Sell
6,260
-1,202
-16% -$36.3K 0.04% 88
2023
Q3
$248K Buy
7,462
+1,212
+19% +$42.9K 0.06% 62
2023
Q2
$229K Buy
6,250
+1,840
+42% +$71.6K 0.06% 69
2023
Q1
$180K Buy
4,410
+648
+17% +$28K 0.05% 81
2022
Q4
$193K Buy
3,762
+103
+3% +$4.94K 0.06% 72
2022
Q3
$160K Buy
+3,659
New +$178K 0.05% 90
2022
Q1
$160K Sell
3,091
-180
-6% -$9.34K 0.05% 103
2021
Q4
$193K Buy
+3,271
New +$162K 0.06% 94

Other funds holding PFE

SJS Investment Consulting's PFE Position: Q2 2026 in Review

SJS Investment Consulting increased its Pfizer (PFE) stake by 8.3% in Q2 2026, buying an estimated $11K and bringing the position to 5,482 shares worth $132K. The position accounts for 0.01% of the portfolio, ranked #200.

SJS Investment Consulting first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. The position peaked at $248K in Q3 2023. 1,139 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • SJS Investment Consulting held 5,482 shares of Pfizer worth $132K as of Q2 2026.
  • SJS Investment Consulting bought 420 Pfizer shares in Q2 2026, an estimated $11K.
  • Pfizer made up 0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #200 holding.
  • SJS Investment Consulting first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • SJS Investment Consulting's Pfizer position peaked at $248K in Q3 2023.
  • 1,139 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.